Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Coronavirus vaccine - GeoVax Labs

Drug Profile

Coronavirus vaccine - GeoVax Labs

Alternative Names: Wuhan coronavirus (2019-nCoV) vaccine - GeoVax Labs

Latest Information Update: 02 Apr 2020

At a glance

  • Originator GeoVax Labs
  • Class DNA vaccines; Viral vaccines; Virus-like particle vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Research COVID 2019 infections

Most Recent Events

  • 30 Mar 2020 GeoVax Labs plans preclinical development in COVID-2019 infections (Prevention)
  • 18 Mar 2020 GeoVax plans a clinical trial for COVID-19 infections before the end of 2020
  • 27 Jan 2020 GeoVax entered into a research and development agreement with BravoVax for the development of Coronavirus vaccine

Development Overview

Introduction

A DNA-based coronavirus vaccine is being developed by GeoVax, in collaboration with Bravovax, for the prevention of coronavirus disease 2019 (COVID-2019) infections. Geovax is using its modified vaccinia ankara-virus-like particles (MVA-VLP/GV-MVA-VLPTM) platform, which generates non-infectious VLPs, mimicking a natural infection to trigger the body of an individual being vaccinated to produce a robust and durable immune response with both antibodies and T cells. The company has designed, constructed, and characterised three vaccine candidates, of which one will be selected in accordance with results from preclinical studies. Early research is underway in the US.

Company Agreements

In January 2020, GeoVax entered into a research and development agreement with BravoVax for the development vaccine against COVID-2019 infections. Unders the terms of agreement, GeoVax will utilise its MVA-VLP vaccine platform and expertise to design and construct the vaccine using genetic sequences from the ongoing coronavirus. BravoVax will provide further development, including testing and manufacturing support, as well as direct interactions with Chinese public health and regulatory authorities. [1]

Key Development Milestones

GeoVax Labs plans to initiate human clinical trial before the end of 2020 [2] .

In March 2020, GeoVax reported that it plans to conduct preclinical studies of three vaccine candidates for prevention of COVID-2019 infections [3] .

Drug Properties & Chemical Synopsis

  • Formulation unspecified
  • Class DNA vaccines, Viral vaccines, Virus-like particle vaccines
  • Mechanism of Action Immunostimulants
  • WHO ATC code

    J07B-X (Other viral vaccines)

  • EPhMRA code

    J7A9 (Other specified single component)

Development Status

Summary Table

Indication Qualifier Patient Segment Phase Countries Route / Formulation Developers Event Date
COVID 2019 infections - Prevention Research USA unspecified / unspecified GeoVax Labs 27 Jan 2020

Commercial Information

Involved Organisations

Organisation Involvement Countries
GeoVax Labs Originator USA
GeoVax Labs Owner USA
BravoVax Collaborator China

Future Events

Expected Date Event Type Description Updated
31 Dec 2020 Trial Update GeoVax plans a clinical trial for COVID-19 infections before the end of 2020 [2] 30 Mar 2020

Development History

Event Date Update Type Comment
30 Mar 2020 Trial Update GeoVax Labs plans preclinical development in COVID-2019 infections (Prevention) [3] Updated 02 Apr 2020
18 Mar 2020 Trial Update GeoVax plans a clinical trial for COVID-19 infections before the end of 2020 [2] Updated 30 Mar 2020
27 Jan 2020 Licensing Status GeoVax entered into a research and development agreement with BravoVax for the development of Coronavirus vaccine [1] Updated 04 Feb 2020
27 Jan 2020 Phase Change Early research in COVID-2019-infections (Prevention) in USA (unspecified route) [1] Updated 04 Feb 2020

References

  1. GeoVax and BravoVax (Wuhan, China) to Collaborate on Development of Coronavirus Vaccine.

    Media Release
  2. GeoVax Progresses in Coronavirus (COVID-19) Vaccine Development Program.

    Media Release
  3. GeoVax Applauds and Comments on Passage of $2 Trillion CARES Act.

    Media Release
Back to top